Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders

Dallas, TX -- (SBWIRE) -- 10/16/2012 -- RnRMarketResearch.com adds new market report “Global Markets for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders” to its store.

- The global market for treatments for syndromes of progressive ataxia and weakness disorders was valued at nearly $14 billion in 2011 and should reach nearly $15 billion in 2012. Total market value is expected to reach nearly $23.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.4%.
- Treatments for progressive weakness syndromes should total nearly $14.6 billion in 2012 and $22.8 billion in 2017, a CAGR of 9.4%.
- Progressive ataxia treatments are expected to have a value of $356.4 million in 2012 and $620.7 million in 2017, a CAGR of 11.7%.

STUDY OBJECTIVES
BCC’s goal in conducting this study is to provide an overview of the current and future characteristics of the global market for treatments of neurodegenerative (i.e., progressive ataxia and weakness) disorders. The key objective is to present a comprehensive analysis and the future direction of treatments for these disorders as the market efforts toward drug and therapy development evolve.

This report explores present and future strategies within the progressive ataxia and weakness disorders market, which includes treatments and therapies for dysfunctions, including progressive ataxia and progressive weakness disorder syndromes. The market’s improvisation, setbacks and needs are also discussed. The comparisons, usage, advantages and disadvantages of different types of technologies, including small-molecule and monoclonal antibodies, are also presented.
A detailed analysis of the industry structure has been conducted. Revenues are broken down by the neurodegenerative dysfunction. Sales figures are estimated for the five-year period from 2012 through 2017.

The report discusses applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology. The report also covers significant patents and their allotments in each category.

REASONS FOR DOING THIS STUDY
Extensive research in the field of progressive ataxia and weakness disorders as well as collaborations with research institutes have highlighted the importance of understanding the nature of these disorders. New technology development is providing modifying therapies for the late stages of these disorders. Collaborations among research institutes and pharmaceutical companies are becoming more common, as state-of-the-art technology is being explored to develop more-efficient products and therapies.

R&D spending, increasing competition, patent expiries and new technologies are shifting the market in a new direction. The market’s overall revenue has increased from 2009 to 2011, and it continues to show growth, as new advancements, product launches and collaborations will have positive influences for the foreseeable future. This study looks at most of the systems affected by these factors.
Acquisition strategies and company collaborations are also covered in this report. This study discusses the strength and weaknesses of each technology in light of the new developments, growing competition and changing customer needs.

CONTRIBUTIONS OF THE STUDY AND FOR WHOM
This study contributes to the areas of market growth in Friedreich’s ataxia, Gerstmann-Straussler-Scheinker disease, Machado-Joseph disease, amyotrophic lateral sclerosis, progressive bulbar palsy, hereditary spastic paraplegia, hereditary neuropathies and multiple sclerosis. Pharmaceutical biotechnical companies, research institutes and physicians will find this study of interest.

SCOPE OF THE STUDY
The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the regulatory environments, and the technologies involved, as well as market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes such countries as India, China, Japan, South Korea, Taiwan, Canada, Africa, Australia and New Zealand.

METHODOLOGY
Both primary and secondary research methodologies were used in preparing this study. BCC conducted a comprehensive literature search, which included technical newsletters and journals, among other sources. Data were collected through interviews and correspondence with technical experts at companies that manufacture enzyme inhibitors. Projections were based on estimates that were calculated such using information as the current number of end users, potential end users, mergers and acquisitions, and market trends.

INFORMATION SOURCES
Many companies within the industry were surveyed to obtain data for this study. These included manufacturers and end users of enzyme inhibitors in therapeutic categories and various disease-sector industries. Data were gathered from various industry sources. BCC spoke with officials within the industry and also reviewed newsletters, company literature and product literature, as well as a host of technical articles, journals, indices and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.

Buy your copy of this report @ http://www.rnrmarketresearch.com/global-markets-for-treatments-for-syndromes-of-progressive-ataxia-and-weakness-disorders-market-report.html .

Major Company Profiles
1. Abbott Laboratories
2. Acorda Therapeutics Inc.
3. Actavis Elizabeth
4. Allon Therapeutics Inc
5. American Regent Inc.
6. Apotex Inc.
7. Apotheca, Inc.
8. App Pharmaceuticals
9. Astellas Pharma Inc.
10. Astrazeneca Gmbh
11. Aurobindo Pharma Ltd
12. Baxter International Inc.
13. Biogen Idec
14. Boehringer Ingelheim Ltd.
15. Bristol-Myers Squibb
16. Bryant Ranch Prepack
17. Cadila Healthcare Ltd.
18. Caraco Pharmaceutical Laboratories
19. Cardinal Health
20. Cognition Pharmaceuticals Llc
21. Csl Behring
22. Dr. Reddy's Laboratories Limited
23. Eisai Co. Ltd
24. Elan Pharma International Limited
25. Eli Lilly And Company
26. Emd Millipore Headquarters
27. Endo Pharmaceuticals Inc
28. Glaxosmithkline Plc.
29. Glenmark Generics Limited
30. H. Lundbeck A/S
31. Hameln Pharmaceuticals Ltd
32. Hospira Inc.
33. Intellect Neurosciences Inc.
34. Jazz Pharmaceuticals Plc.
35. Lexicon Pharmaceuticals Inc.
36. Major Pharmaceuticals
37. Merck Serono
38. Merck Sharp & Dohme Limited
39. Merz Pharma Gmbh & Co Kgaa
40. Momenta Pharmaceuticals
41. Mylan Pharmaceuticals
42. Neuren Pharmaceuticals Ltd.
43. Neurosearch A/S
44. Noscira, S.A.
45. Novartis Ag
46. Orchid Chemicals & Pharmaceuticals Ltd.
47. Ortho-Mcneil Janssen Pharmaceuticals Inc.
48. Par Pharmaceuticals
49. Perrigo Company
50. Pfizer Inc.
51. Pharnext
52. Physicians Total Care, Inc.
53. Pliva Hrvatska D.O.O.
54. Prometheus
55. Ranbaxy Laboratories Limited
56. Roche Holding Ltd
57. Roxane Laboratories Inc.
58. Sandoz International Gmbh
59. Sanofi
60. Santhera Pharmaceuticals
61. Shionogi & Co.
62. Sun Pharma
63. Taj Pharmaceuticals Limited
64. Takeda Pharmaceutical Company Limited
65. Tercica, Inc
66. Teva Pharmaceutical Industries Ltd
67. Torrent Pharma
68. Ucb S.A.
69. Udl Laboratories
70. Upsher-Smith Laboratories
71. Watson Pharmaceuticals Inc.
72. West-Ward Pharmaceutical

List Of Tables
Summary Table : Global Market For Progressive Ataxia And Weakness Disorders, Through 2017
Table 1 : Classification By Primary Dysfunction
Table 2 : Abbreviated Approvals And New Drug Approvals For Progressive Ataxia And Weakness Disorders, 2012
Table 3 : New Drug Applications For The Progressive Ataxia And Weakness Disorders
Table 4 : Safety Alerts, 2010-March 2012
Table 5 : Recalls For Drugs Used To Treat Progressive Ataxia And Weakness Disorders, 2010–March 2012
Table 6 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders, 2012
Table 7 : New Developments For The Treatment Of Progressive Ataxia And Weakness Disorders, 2011
Table 8 : New Developments In The Treatment Of Progressive Ataxia And Weakness Disorders, 2010
Table 9 : Global Revenues Of Drug Products For The Treatment Of Neurodegenerative Dysfunctions, Through 2017
Table 10 : Market Share Of Drugs Used For The Treatment Of Neurodegenerative Disorders By Dysfunctions, 2011
Table 11 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders, Through 2017
Table 12 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders, 2011
Table 13 : Market For Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Region, Through 2017
Table 14 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Region, 2011
Table 15 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Technology, Through 2017
Table 16 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Technology, 2011
Table 17 : Sales Of Drug Products For The Treatment Of Progressive Ataxia By Disease Type, Through 2017
Table 18 : Progressive Ataxia Drug Market By Disease Type, 2011
Table 19 : Progressive Ataxia Drug Market By Region, Through 2017
Table 20 : Progressive Ataxia Drug Market By Region, 2011
Table 21 : Friedreich’s Ataxia Drug Market By Region, Through 2017
Table 22 : Gertsmann-Straussler-Scheinker Disease Drug Market By Region, Through 2017
Table 23 : Machado-Joseph Disease Drug Market By Region, Through 2017
Table 24 : Progressive Ataxia Drug Market By Technology, Through 2017
Table 25 : Progressive Ataxia Drugs Share By Technology, 2011
Table 26 : Leading Manufacturers And Suppliers Of Friedreich’s Ataxia Drugs And Therapies
Table 27 : Market Shares For Manufacturers And Distributors Of Friedreich’s Ataxia Drugs, 2011
Table 28 : Leading Manufacturers And Suppliers Of Gerstmann-Straussler-Scheinker Disease Drugs And Therapies
Table 29 : Market Shares Of Manufacturers And Distributors Of Gertsmann-Straussler-Scheinker Disease Drugs, 2011
Table 30 : Leading Manufacturers And Suppliers Of Machado-Joseph Disease Drugs And Therapies
Table 31 : Market Shares Of Manufacturers And Distributors Of Machado-Joseph Disease Drugs, 2011
Table 32 : Progressive Weakness Syndrome Drug Market By Disease Type, Through 2017
Table 33 : Progressive Weakness Drug Market By Disease Type, 2011
Table 34 : Progressive Weakness Syndrome Drug Market By Region, Through 2017
Table 35 : Progressive Weakness Drug Market By Region, 2011
Table 36 : Amyotrophic Lateral Sclerosis Drug Market By Region, Through 2017
Table 37 : Progressive Bulbar Palsy Drug Market By Region, Through 2017
Table 38 : Hereditary Spastic Paraplegia Drug Market By Region, Through 2017
Table 39 : Hereditary Neuropathy Drug Market By Region, Through 2017
Table 40 : Multiple Sclerosis Drug Market By Region, Through 2017
Table 41 : Progressive Weakness Syndrome Drug Market By Technology, Through 2017
Table 42 : Progressive Weakness Market By Technology, 2011
Table 43 : Multiple Sclerosis Drug Market By Technology, Through 2017
Table 44 : Multiple Sclerosis Drug Market Distribution By Technology, 2011
Table 45 : Leading Manufacturers And Suppliers Of Drugs And Therapies For Amyotrophic Lateral Sclerosis
Table 46 : Market Shares Of Manufacturers And Distributors Amyotrophic Lateral Sclerosis Drugs, 2011
Table 47 : Leading Manufacturers And Suppliers Of Progressive Bulbar Palsy Drugs And Therapies
Table 48 : Market Shares Of Manufacturers And Distributors Of Progressive Bulbar Palsy Drugs, 2011
Table 49 : Leading Manufacturers And Suppliers Of Hereditary Spastic Paraplegia Drugs And Therapies
Table 50 : Market Shares Of Manufacturers And Distributors Of Hereditary Spastic Paraplegia Drugs, 2011
Table 51 : Leading Manufacturers And Suppliers Of Hereditary Neuropathy Drugs And Therapies
Table 52 : Market Shares Of Manufacturers And Distributors Of Hereditary Neuropathies Drugs, 2011
Table 53 : Leading Manufacturers And Suppliers Multiple Sclerosis Drugs And Therapies
Table 54 : Market Shares Of Manufacturers And Distributors Of Multiple Sclerosis Drugs, 2011
Table 55 : Total Number Of Patents By Year, 2010-March 2012
Table 56 : Patents By Disease Category, 2010-March 2012
Table 57 : Patents For Progressive Ataxia Syndromes By Disease Type, 2010-2012
Table 58 : Patents For Progressive Weakness And Effect The On Brain And Spinal Cord Syndromes By Disease Type, 2010-2012
Table 59 : U.S. Patents By Country For Progressive Ataxia Syndromes, 2010-2012
Table 60 : Patent Shares By Country For Progressive Ataxia Syndromes, 2010-2012
Table 61 : U.S. Patents By Country For Progressive Weakness And Effect On The Brain And Spinal Cord Syndromes, 2010-2012
Table 62 : Patent Shares By Country For Progressive Weakness And Effect On The Brain And Spinal Cord Syndromes, 2010-2012
Table 63 : U.S. Patents For Progressive Ataxia Syndromes By Company, 2010-2012
Table 64 : U.S. Patents For Progressive Weakness And Effect On The Brain And Spinal Cord Syndromes By Company, 2010-2012
Table 65 : Patents For Progressive Ataxia Syndromes By Assignee, 2010-2012
Table 66 : Patents For Progressive Weakness And Effect On The Brain And Spinal Cord Syndromes By Assignee, 2010-2012

List Of Figures
Summary Figure : Global Market For Progressive Ataxia And Weakness Disorders, 2010-2017
Figure 1 : Global Revenues Of Drug Product For The Treatment Of Neurodegenerative Dysfunctions, 2010-2017
Figure 2 : Market Share Of Drug Used For The Treatment Of Neurodegenerative Disorders By Dysfunction, 2011
Figure 3 : Global Sales Of Drug Product For The Treatment Of Progressive Ataxia And Weakness Disorders, 2010-2017
Figure 4 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders, 2011
Figure 5 : Market For Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Region, 2010-2017
Figure 6 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Region, 2011
Figure 7 : Global Sales Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Technology, 2010-2017
Figure 8 : Market Share Of Drug Products For The Treatment Of Progressive Ataxia And Weakness Disorders By Technology, 2011
Figure 9 : Sales Of Drug Products For The Treatment Of Progressive Ataxia By Disease Type, 2010-2017
Figure 10 : Progressive Ataxia Drug Market By Disease Type, 2011
Figure 11 : Progressive Ataxia Drug Market By Region, 2010-2017
Figure 12 : Progressive Ataxia Drug Market By Region, 2011
Figure 13 : Friedreich’s Ataxia Drug Market By Region, 2010-2017
Figure 14 : Gertsmann-Straussler-Scheinker Disease Drug Market By Region, 2010-2017
Figure 15 : Machado-Joseph Disease Drug Market By Region, 2010-2017
Figure 16 : Progressive Ataxia Drug Market By Technology, 2010-2017
Figure 17 : Progressive Ataxia Drugs Share By Technology, 2011
Figure 18 : Market Shares Of Manufacturers And Distributors Of Friedreich’s Ataxia Drugs, 2011
Figure 19 : Market Shares Of Manufacturers And Distributors Of Gertsmann-Straussler-Scheinker Disease Drugs, 2011
Figure 20 : Market Shares Of Manufacturers And Distributors Of Machado-Joseph Disease Drugs, 2011
Figure 21 : Progressive Weakness Syndrome Drug Market By Disease Type, 2010-2017
Figure 22 : Progressive Weakness Drug Market By Disease Type, 2011
Figure 23 : Progressive Weakness Syndrome Drug Market By Region, 2010-2017
Figure 24 : Progressive Weakness Drug Market By Region, 2011
Figure 25 : Amyotrophic Lateral Sclerosis Drug Market By Region, 2010-2017
Figure 26 : Progressive Bulbar Palsy Drug Market By Region, 2010-2017
Figure 27 : Hereditary Spastic Paraplegia Drug Market By Region, 2010-2017
Figure 28 : Hereditary Neuropathy Drug Market By Region, 2010-2017
Figure 29 : Multiple Sclerosis Drug Market By Region, 2010-2017
Figure 30 : Progressive Weakness Syndrome Drug Market By Technology, 2010-2017
Figure 31 : Progressive Weakness Market By Technology, 2011
Figure 32 : Multiple Sclerosis Drug Market By Technology, 2010-2017
Figure 33 : Multiple Sclerosis Drug Market Distribution By Technology, 2011
Figure 34 : Market Shares Of Manufacturers And Distributors Of Amyotrophic Lateral Sclerosis Drugs, 2011
Figure 35 : Market Shares Of Manufacturers And Distributors Of Progressive Bulbar Palsy Drugs, 2011
Figure 36 : Market Shares Of Manufacturers And Distributors Of Hereditary Spastic Paraplegia Drugs, 2011
Figure 37 : Market Shares Of Manufacturers And Distributors Of Hereditary Neuropathy Drugs, 2011
Figure 38 : Market Shares Of Manufacturers And Distributors Of Multiple Sclerosis, Drugs 2011
Figure 39 : Number Of Patents By Year, 2010–March 2012
Figure 40 : Patents By Disease Category, 2010–March 2012
Figure 41 : Patents For Progressive Ataxia Syndromes By Disease Type, 2010–2012
Figure 42 : Patents For Progressive Weakness And Effect On Brain And Spinal Cord Syndromes By Disease Type, 2010–2012

Browse more reports on Pharmaceuticals Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .

Contact sales@rnrmarketresearch.com for further information.